RecruitingAlzheimer s DiseaseMCI Conversion to DementiapTau217
Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
Eligible age
40–90 yrs
Accepts
All genders
Locations
3 states
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.
Sponsor: Neurogen Biomarking LLC
You may qualify if…
- ✓ AD Amyloid PET/CSF confirmed, healthy control, or amyloid-negative non-AD cognitive impairment Age 40-90 Able to complete Tasso and venipuncture collection Caregiver consent/assistance available if needed
You may not qualify if…
- ✕ Uncontrolled systemic conditions Recent surgery/hospitalization (3 months) Other dementia drug trial (2 months) Pregnancy Prior Donanemab or Lecanemab use
Where it's recruiting
Source: ClinicalTrials.gov · NCT07701161 · last updated 2026-07-14